China's Xuanzhu Biopharmaceutical Soars 158% in Hong Kong Grey Market
View all comments(0)
Xuanzhu Biopharmaceutical, which is being spun off from China's Sihuan Pharmaceutical, soared 158% in Hong Kong grey market.

Last year, the company expanded its net loss by 85.1 percent to 556.4 million yuan (HK$608.3 million), while its revenue surged 1036.7 times to 30.1 million yuan from its core product KBP-3571 for digestive diseases during the period.
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Like
Recommended Articles
Featured Tools
Top News
Meta Connect 2026 New Product Roundup: Muse Integrated Into AI Glasses, Can It Drive Meta Revenue Growth?

Qualcomm Extends Long-Term Patent Agreement With Apple, Securing QTL Revenue in Era of In-House iPhone Modems

Oracle Tumbles 7% as Project Jupiter Data Center Force Majeure Notice Sparks Delay Concerns

Meta Stock Forecast: Muse Monetization Path Is Key as JPMorgan Raises Price Target to $920; Can Stock Hit Record High?

US Stocks Mixed as Dow Drops 160 Points; Tech Stocks Lead, Meta Rises 4.5%





Comments (0)
Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.